Neo-antigens are mutated tumor antigens, mostly specific for each patient.
Recent technical advancement enabled personalized vaccines that target neo-antigens.
Autologous tumor cells or tumor-pulsed DCs can be used for personalized vaccination.
Autologous tumor vaccines may provide the full repertoire of tumor antigens.
Combination strategies could be the key for effective personalized vaccination.